Small Cell Lung Cancer Extensive Stage clinical trials

Explore recruiting small cell lung cancer extensive stage clinical trials.

Recruiting small cell lung cancer extensive stage studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Small Cell Lung Cancer Extensive Stage trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

Netherlands, Norway, Iceland, Estonia, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy

Bulgaria, Poland, Belgium, Germany, Spain, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

Portugal, Germany, Spain, Italy, Denmark, Netherlands +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive‑stage Small Cell Lung Cancer (ES‑SCLC) (IDeate-Lung03).

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

Spain, Germany, Poland, Belgium, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Small Cell Lung Cancer Extensive Stage trials by city

Small Cell Lung Cancer Extensive Stage in Toronto Small Cell Lung Cancer Extensive Stage in Vancouver Small Cell Lung Cancer Extensive Stage in Montreal Small Cell Lung Cancer Extensive Stage in Calgary Small Cell Lung Cancer Extensive Stage in Edmonton Small Cell Lung Cancer Extensive Stage in Ottawa Small Cell Lung Cancer Extensive Stage in Winnipeg Small Cell Lung Cancer Extensive Stage in Quebec City Small Cell Lung Cancer Extensive Stage in Hamilton Small Cell Lung Cancer Extensive Stage in Kitchener Small Cell Lung Cancer Extensive Stage in London Small Cell Lung Cancer Extensive Stage in Halifax Small Cell Lung Cancer Extensive Stage in New York Small Cell Lung Cancer Extensive Stage in Los Angeles Small Cell Lung Cancer Extensive Stage in Chicago Small Cell Lung Cancer Extensive Stage in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease